VRDN
Viridian Therapeutics, Inc.\DECompany Information
- Company Name
- Viridian Therapeutics, Inc.\DE
- CIK
- CIK0001590750
- Category
- Large accelerated filer
- Ticker: Exchange
- VRDN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- VRDN
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-11
- Last sale
- 2026-08-19
- Shares purchased (TTM)
- 1,631,015
- Shares sold (TTM)
- 16,484
Institutional Sentiment
- As of
- 2025-09-30
- Institutional shares owned
- 4,180
- Shares outstanding
- 81,784,499
- Ownership
- 0.01%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 2.53%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 165 | 176 | 212 | 170 | 117 | 116 | 100 | 200 | 108 | 92 | 103 | 112 | ||||||
| Available For Sale Securities Debt Securities Current | 817 | 586 | 662 | 321 | 446 | 520 | 618 | 553 | 464 | 522 | 375 | 201 | ||||||
| Contract With Customer Asset Net Current | - | - | - | 70 | - | - | - | - | - | - | - | - | ||||||
| Other Receivables Net Current | 75 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 25 | 23 | 20 | 11 | 15 | 21 | 21 | 14 | 10 | 14 | 9 | 11 | ||||||
| Contract With Customer Asset Net | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 1,081 | 785 | 894 | 572 | 579 | 657 | 738 | 767 | 582 | 627 | 486 | 324 | ||||||
| Property Plant And Equipment Net | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | ||||||
| Finite Lived Intangible Assets Net | 10 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 1 | 1 | 2 | 2 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 1,097 | 789 | 899 | 577 | 582 | 661 | 742 | 772 | 586 | 630 | 490 | 329 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 9 | 13 | 9 | 10 | 9 | 4 | 2 | 6 | 3 | 3 | 2 | 4 | ||||||
| Accrued Liabilities Current | 55 | 38 | 62 | 41 | 35 | 30 | 46 | 35 | 30 | 23 | 24 | 19 | ||||||
| Long Term Debt Current | - | - | - | - | 8 | - | - | - | 3 | - | - | - | ||||||
| Liabilities Current | 64 | 52 | 71 | 51 | 53 | 34 | 48 | 41 | 37 | 26 | 27 | 23 | ||||||
| Long Term Debt | - | - | - | - | - | - | - | - | - | 20 | 20 | 20 | ||||||
| Long Term Debt Noncurrent | - | - | - | 21 | 12 | 21 | 21 | 21 | 17 | - | 20 | - | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Contract With Customer Liability Current | - | - | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Secured Long Term Debt | 0 | 50 | 50 | - | - | - | 21 | - | - | - | - | - | ||||||
| Derivative Liabilities Noncurrent | 14 | 13 | 20 | - | - | - | 0 | - | - | - | - | - | ||||||
| Other Long Term Debt Noncurrent | 114 | 36 | 34 | - | - | - | 0 | - | - | - | - | - | ||||||
| Convertible Long Term Notes Payable | 242 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | ||||||
| Liabilities | 435 | 153 | 177 | 74 | 67 | 57 | 71 | 64 | 56 | 48 | 48 | 45 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Additional Paid In Capital | 2,135 | 1,947 | 1,927 | 1,531 | 1,509 | 1,497 | 1,478 | 1,433 | 1,169 | 1,157 | 961 | 807 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | 0 | 0 | 0 | 0 | -0 | 1 | -1 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,570 | -1,443 | -1,338 | -1,218 | -1,184 | -1,083 | -996 | -916 | -839 | -774 | -726 | -659 | ||||||
| Stockholders Equity | 662 | 636 | 722 | 503 | 515 | 604 | 672 | 707 | 529 | 583 | 442 | 284 | ||||||
| Related Party | - | - | - | - | 0 | 0 | 1 | 3 | -1 | 1 | 0 | -1 | ||||||
| Liabilities And Stockholders Equity | 1,097 | 789 | 899 | 577 | 582 | 661 | 742 | 772 | 586 | 630 | 490 | 329 | ||||||
| Series A Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | ||||||
| Series B Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | - | - | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 113 | 102 | 102 | 82 | 82 | 82 | 81 | 79 | 64 | 64 | 54 | 44 | ||||||
| Shares Outstanding | 113 | 102 | 102 | 82 | 82 | 82 | 81 | 79 | 64 | 64 | 54 | 44 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialViridian Therapeutics, Inc.\DE (VRDN) — SEC Financial Statements & Analysis
Viridian Therapeutics, Inc.\DE (VRDN) is a pharmaceutical preparations company, incorporated in DE. Viridian Therapeutics, Inc.\DE trades on Nasdaq as: VRDN. Viridian Therapeutics, Inc.\DE (VRDN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Viridian Therapeutics, Inc.\DE carries a market cap of $1.98B, a P/E ratio of -5.12x, a P/B ratio of 2.99x, a P/S ratio of 27.86x, an enterprise value of $2.06B, and an EV/EBITDA multiple of -5.09x. On profitability, it posts an operating margin of -569.68%, a net margin of -544.06%, a Return on Equity (ROE) of -65.74%, a Return on Assets (ROA) of -46.08%, and a Return on Invested Capital (ROIC) of -69.90%. Per share, it reports EPS of $-3.59, diluted EPS of $-3.59, free cash flow per share of $-3.11, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 23220.33% year-over-year, net income growth of 12.47% year-over-year, and EPS growth of -14.94% year-over-year. On the balance sheet, it maintains a current ratio of 16.95x, a quick ratio of 16.56x, working capital of $1.02B, a debt-to-equity ratio of 0.66x, a debt ratio of 0.4, an interest coverage ratio of -25.89x, free cash flow of $-335.04M (TTM), and net debt of $77.17M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.98B
- P/E TTM
- -5.12x
- EPS TTM
- $-3.59
- P/B TTM
- 2.99x
- ROE TTM
- -65.74%
- ROA TTM
- -46.08%
- Debt To Equity
- 0.66x
- Free Cash Flow TTM
- $-335.04M
- Net Revenue TTM Growth 1Y
- 23220.33%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Viridian Therapeutics, Inc.\DE in?
Viridian Therapeutics, Inc.\DE (VRDN) operates in the Pharmaceutical Preparations industry.
What exchange does VRDN trade on?
Viridian Therapeutics, Inc.\DE (VRDN) trades on the Nasdaq.
Where is Viridian Therapeutics, Inc.\DE incorporated?
Viridian Therapeutics, Inc.\DE is incorporated in DE.
When was Viridian Therapeutics, Inc.\DE (VRDN)'s most recent SEC filing?
Viridian Therapeutics, Inc.\DE (VRDN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is VRDN's market cap?
Viridian Therapeutics, Inc.\DE (VRDN) has a market capitalization of $1.98B as of 2026-06-30.
What is VRDN's EPS (earnings per share)?
Viridian Therapeutics, Inc.\DE (VRDN)'s trailing twelve month EPS is $-3.59 as of 2026-06-30.
What is VRDN's ROE (return on equity)?
Viridian Therapeutics, Inc.\DE (VRDN)'s trailing twelve month Return on Equity (ROE) is -65.74% as of 2026-06-30.
What is VRDN's ROA (return on assets)?
Viridian Therapeutics, Inc.\DE (VRDN)'s trailing twelve month Return on Assets (ROA) is -46.08% as of 2026-06-30.
What is VRDN's ROIC (return on invested capital)?
Viridian Therapeutics, Inc.\DE (VRDN)'s trailing twelve month Return on Invested Capital (ROIC) is -69.90% as of 2026-06-30.
What is VRDN's EV/EBITDA?
Viridian Therapeutics, Inc.\DE (VRDN)'s trailing twelve month EV/EBITDA is -5.09x as of 2026-06-30.